The Traderszone Network

Published in TZ Latest News 22 August, 2017 by The TZ Newswire Staff

Why Eylea Is Still Regeneron Pharmaceuticals’ Most Important Drug

Aging baby boomers are turning 65 years old at a pace of 10,000 per day, and that’s causing an increase in the diagnosis of common causes of vision loss, including age-related macular degeneration and diabetic macular edema. Patients with these conditions are increasingly being prescribed Regeneron Pharmaceuticals‘ (NASDAQ: REGN) Eylea, and as a result, Eylea’s selling at a $6 billion annualized clip globally.

read more